START-MET HS Prostate Cancer: SbrT & Androgen Receptor Therapy METastatic HSPC.

Datos básicos

Código:
START-MET
Protocolo:
START-MET
EUDRACT:
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:
2023
Año de finalización:
ENSAYO CLÍNICO NACIONAL Finan. No Competitiva Pública

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

FEOR, FUNDACIÓN ESPAÑOLA DE ONCOLOGÍA RADIOTERÁPICA

Resultados del Ensayo Clínico


A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05).

Conde-Moreno, Antonio J; (...); Ferrer, Carlos

Article. 10.1016/j.prro.2024.04.022. 2024


A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24.

González-San Segundo C; (...); Couñago F

Article. 10.1111/bju.16484. 2024


Clinical practice guidelines for the treatment of Ewing sarcoma (Spanish Sarcoma Research Group-GEIS).

Mata Fernández C; (...); Valverde Morales C

Article. 10.1007/s12094-024-03602-5. 2024


Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01

Sands, J.; (...); Ahn, M-J

Meeting Abstract. 2024


Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).

Marquez-Rodas, Ivan; (...); Berrocal, Alfonso

Article. 10.1093/neuonc/noae116. 2024


Evaluation of EMBARK criteria patients. Real-world data on prostate cancer biochemical recurrence

Centelles Hidalgo, Elena; (...); Lopez-Campos, Fernando

Meeting Abstract. 2024


Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer.

Deek MP; (...); Sweeney C

Article. 10.1016/j.euo.2024.03.010. 2024


PEACE V-Salvage Treatment of oligorecurrent nodal prostate cancer metastases (STORM): 24-months toxicity results of a randomized phase II trial

Zilli, T.; (...); Ost, P.

Meeting Abstract. 2024

  • Open Access.

Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM)

Ost, Piet; (...); Moon, Daniel

Meeting Abstract. 2024


Campos de estudio

Compartir